Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 30th September 2025
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 5.8% | -7.3% | - |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 5.8% | -7.3% | - |
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Oct 24 2025 | 2025 Q3 | FN, FOUR, FRPT, INSP, MEDP, OPEN, SG | AI, Quality, Shorting, small caps, Speculation | - | The fund declined as speculative, unprofitable small caps surged on AI and quantum themes. Managers describe the market as highly euphoric, reminiscent of 202021. They… |
| Jul 21 2025 | 2025 Q2 | FN, GWRE, HQY, INSP, NSA, RKLB, SG, SKY | Defensive, Long/Short, Quality, valuation |
SKY NSA INSP GWRE HQY |
- |
| Mar 31 2025 | 2025 Q1 | AGYS, BROS, FRPT, GLOB, ITCI, RBC | - | - | - |
| Dec 31 2024 | 2024 Q4 | ACHC, FND, HQY, ICFI, IONQ, PCTY | - | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q3 |
AIAI has become a dominant theme across major equity indices, with Nvidia leading the S&P 500, ASML dominating MSCI EAFE, and TSMC leading emerging markets. The fund benefited from AI-related dynamics, particularly through Samsung's memory products experiencing substantial price increases due to DRAM shortages driven by AI demand. |
Semiconductors Memory DRAM Technology Nvidia |
Small CapsConcentrated portfolio of small-cap companies with limited sell-side coverage and institutional ownership. Invests where most institutional managers cannot or will not participate, allowing for asymmetric return potential. 44% of Russell 2000 stocks have zero Wall Street coverage, creating mispriced opportunities. |
Russell 2000 Limited Coverage Institutional Asymmetric Mispriced | |
| 2025 Q2 |
Long/Short |
|
Quality Growth |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 21, 2025 | Fund Letters | Mick Rasmussen | SKY | Champion Homes, Inc. | Consumer Discretionary | Homebuilding | Neutral | New York Stock Exchange | affordability, Housing, Interestrates, Margins, Modularhousing | Login |
| Jul 21, 2025 | Fund Letters | Mick Rasmussen | NSA | National Storage Affiliates Trust | Real Estate | Self-Storage REIT | Bull | New York Stock Exchange | Acquisitions, consolidation, Interestrates, REIT, Selfstorage | Login |
| Jul 21, 2025 | Fund Letters | Mick Rasmussen | INSP | Inspire Medical Systems, Inc. | Health Care | Medical Devices | Bull | New York Stock Exchange | Adoption, innovation, Medicaldevices, Procedures, Sleepapnea | Login |
| Jul 21, 2025 | Fund Letters | Mick Rasmussen | GWRE | Guidewire Software, Inc. | Information Technology | Application Software | Bull | New York Stock Exchange | Cloudmigration, Insurancesoftware, Modernization, SaaS, Switchingcosts | Login |
| Jul 21, 2025 | Fund Letters | Mick Rasmussen | HQY | HealthEquity, Inc. | Financials | Asset Management & Custody | Bull | New York Stock Exchange | Custody, cybersecurity, Healthcarefinance, Hsas, Operatingleverage | Login |
| TICKER | COMMENTARY |
|---|---|
| FN | Fabrinet Information Technology 1.6 |
| FOUR | Shift4 (FOUR), over the past 3 years: Revenue per share increased +122%, or +30% annualized. Free Cash Flow per share increased +227%, or +48% annualized. Share Price declined -45% over the past year. FOUR currently trades at 6% free cash flow yield. |
| INSP | Inspire Medical had a difficult first three quarters of the year due to challenges rolling out a new version of their product, and delays setting up reimbursement codes and billing software. The stock rebounded somewhat in the fourth quarter, but it wasn't enough to overcome the weakness earlier in the year. Inspire's product offering and differentiation in the market is still a strength, and supportive of continued leadership in a large addressable market, which is why we have stuck with the stock. |
| MEDP | Medpace was the Fund's largest contributor in H1 FY26, having been among its largest detractors over the prior 12 months. Medpace is a US-listed clinical research organisation focused on small biotechnology companies. After four consecutive quarters of elevated project cancellations, Medpace delivered a strong inflection in fundamentals, reporting very robust net bookings growth in Q2 and Q3 FY25, alongside stronger-than-expected guidance for FY26. |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||